MRK

Merck & Company, Inc.

86.78
USD
-0.83%
86.78
USD
-0.83%
71.50 95.72
52 weeks
52 weeks

Mkt Cap 219.67B

Shares Out 2.53B

Chat
Send me real-time posts from this site at my email

FDA says found possible carcinogen in certain samples of Merck's Januvia

Aug 9 (Reuters) - The U.S. Food and Drug Administration said on Tuesday certain samples of sitagliptin, a compound in Merck's MRK.N diabetes drug Januvia, were contaminated with a possible carcinogen. The agency said it would not object to the temporary distribution of sitagliptin containing the impurity above the acceptable intake limit of 37 nanogram per day, and up to 246.7 nanogram per day to avoid a shortage. Shares of Merck, which was not immediately available for comment, fell sharply before recovering to trade up 0.2% at $88.74. (Reporting by Ankur Banerjee in Bengaluru; Editing by Aditya Soni) ((ankur.banerjee@thomsonreuters.com;; Mobile - +919591691912; Twitter: @AnkurBanerjee17;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Welcome! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue